Session » Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 89

Anti-Nuclear Antibodies (ANA) and Air Pollution: Ultrafine Particles and Ozone

9:00AM-11:00AM: Abstract Number: 107

Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study

9:00AM-11:00AM: Abstract Number: 93

Biomarkers Associating Endothelial Function in Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 94

Circulating Soluble MICA Is Associated to Lupus Nephritis and to a TLR/IFN-I Signature in T Cells in a Cohort of Adult SLE Patients

9:00AM-11:00AM: Abstract Number: 99

DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients

9:00AM-11:00AM: Abstract Number: 90

Deoxyribonuclease 1-like-3 Digests Self-DNA from Dead Cells and Prevents Autoimmunity

9:00AM-11:00AM: Abstract Number: 97

Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 102

Estrogen Controls the Expression of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in Human T Lymphocytes Via Transcriptional and Post-Transcriptional Mechanisms

9:00AM-11:00AM: Abstract Number: 95

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 100

Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 106

Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 104

Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 103

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

9:00AM-11:00AM: Abstract Number: 105

Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials

9:00AM-11:00AM: Abstract Number: 92

Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro

9:00AM-11:00AM: Abstract Number: 98

Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation

9:00AM-11:00AM: Abstract Number: 101

Regulation of Monocyte Function By Epstein Barr Virus Interleukin-10 (vIL10) in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 108

Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis

9:00AM-11:00AM: Abstract Number: 110

Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways

9:00AM-11:00AM: Abstract Number: 96

The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 91

Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE

9:00AM-11:00AM: Abstract Number: 109

Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].